{
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2684, 
        2713
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2715, 
        2732
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        1503, 
        1505
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        2734, 
        2736
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        2960, 
        2962
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        3202, 
        3204
      ]
    }
  ], 
  "__text": "MSH|^~\\&|LABCORP-CORP|LABCORP^34D0655059^CLIA|Cancer Registry|State|201706010938|State006|ORU^R01|2017060107093839521000|P|2.3.1\nOBX|7|TX|^^^500935^SP to detect 5% mutation in a background of wild-type DNA. Intended Use: The detection of a BRAF V600 gene mutation aids in the specific diagnosis of certain cancers, such as hairy cell leukemia, and help to identify patients with worse prognosis and who may be responsive to certain therapies in a variety of cancers. References: Kudchadkar, R. et al. (2014) Integrating molecular biomarkers into current clinical management in melanoma. Methods Mol. Biol. 1102-27-42. Misale, S. et al. (2014) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Disco. 4:1-12. NCCN Clinical Practice Guidelines in OncologyTM for Colon Cancer v.2 2015. NCCN Clinical Practice Guidelines in OncologyTM for Hairy Cell Leukemia. v.4 2014. NCCN Clinical Practice Guidelines in OncologyTM for Rectal Cancer v.2 2015. NCCN Clinical Practice Guidelines in OncologyTM for Thyroid Carcinoma. v.2 2014. NCCN Clinical Practice Guidelines in OncologyTM for Non-Small Cell Lung Cancer. v.1 2015. Ohashi, K. et al. (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. USA. 109:E2127-E2133. Pakneshan, S. et al. (2013) Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45: 346-356. Sharm, S.G. and Gulley, M.L. (2010) BRAF mutation testing in colorectal cancer. Arch. Pathol. Lab. Med. 134-1225-1228. Disclaimer This Test was performed by Accupath Diagnostic Laboratories, Inc. at 5005 S 40th Street, Ste 1100, Phoenix, AZ, 85040. Integrated Oncology is a business unit of Accupath Diagnostic Laboratories, Inc., a wholly-owned subsidiary of Laboratory Corporation of America Holdings. This test was developed and its performance characteristics determined by Accupath Diagnostic Laboratories, Inc.   It has not been cleared or approved by the Food and Drug Administration. A complete copy of the report is on file. Professional services performed by Accupath Diagnostics Inc. at 5005 S. 40th St., Ste 1100, Phoenix, AZ 85040.  Technical services performed by Accupath Diagnostics, Inc. at 5005 S. 40th St., Ste 1100, Phoenix, AZ 85040.||||||C|||20170626223623|26D0652233^LabCorp Overland Park^CLIA|||\n\n\n\n\n\n\nDiagnosis ICD code\n\nPathologist provided ICD-10:C19 D12.3 D12.4\n\n\nPayment procedure\n\nCPT                            .88305 88305 88305 81275 88381 81479 88342 88341 88341 88341 81311 81210\n\n\nPATHOLOGIST NAME\n\nElectronically signed: Pathologist name, Pathologist\n\n\nPath report.gross observation\n\nGross description: A. The specimen is received in formalin, labeled \"Sutherlandrectal sigmoid polyp\" is one tan-pink irregular fragment of soft tissue measuring 0.8 x 0.6 x 0.3 cm. The specimen is filtered and submitted entirely in cassette A1. B. The specimen is received in formalin, labeled \"Sutherlandtransverse colon polyps\" is 3 tan-pink, irregular fragments of soft tissue measuring 0.9 x 0.3 x 0.2 cm in aggregate. The specimen is filtered and submitted entirely in cassette B1. C. The specimen is received in formalin, labeled \"Sutherlanddescending colon polyp\" is one tan-pink irregular fragment of soft tissue measuring 0.3 x 0.3 x 0.2 cm. The specimen is filtered and submitted entirely in cassette C1. (AKA; 6/2/2017)\n\n\n"
}